Findings suggest significant reduction in the risk of CV death and all-cause mortality for T2DM patients with a history of CVD.

Your patient has been taking metformin, glipizide and a daily basal insulin dose (.85 U/kg/day). While his fasting glucose levels are on target, he have not yet been able to reach his individualized glycemic target of A1C<7%. In your discussion with him about the addition of a prandial insulin dose to his regimen, you compare and contrast his options. Compared to basal insulin alone, premixed insulins: Follow link to give your answer!

Under normal circumstances, blood glucose levels vary throughout the day. While it may not be of much significance to a healthy subject, the degree of these changes is of great importance to individuals with diabetes.

Studies have shown that 40-80 percent of the medical information patients receive is forgotten immediately and nearly half of the information retained is incorrect. One of the easiest ways to close the gap of communication between clinician and patient is to employ the “teach-back” method, also known as the “show-me” …

We’re excited to let you know that on October 1st, 2015, we will be relaunching DiabetesInControl.com. The refreshed site will feature a clean, new look and feel, with enhanced navigation to make it even easier to find all our great content. We’ve also decided to make some of our most …

Reminder – on October 1st, 2015, we will be relaunching DiabetesInControl.com. The refreshed site will feature a clean, new look and feel, with enhanced navigation to make it even easier to find all our great content. We’ve also decided to make some of our most popular content, including our “Tools …

Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased...

Dr. Christophe Arbet-Engels talks about how the empagliflozin study results were very positive in terms of lowering A1c, and goes over the basics of how the new class of SGLT-2 inhibitor drugs work, removing excess glucose, inducing some weight loss, and that there is potential for a decrease in blood pressure …

Christophe Arbet-Engels, MD, PhD, MBA, vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc., gives us a brief introduction to himself. Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. See more SGLT-2 Resources

Dr. Christophe Arbet-Engels, discusses some of the study results on empagliflozin in which more than 14,000 patients were involved in several different study configurations including monotherapy, empagliflozin as an add-on, and patients with renal impairment.   Christophe Arbet-Engels, MD, PhD, MBA, is vice president, metabolic-clinical development and medical affairs, Boehringer …